What is Entyvio?

Entyvio (vedolizumab) is a first-in-class, gut-selective biologic treatment for moderately to severely active ulcerative colitis (UC) and moderately to severely active Crohn’s disease (CD).1,2

It’s available in both SC and IV formulations, making it a flexible choice for patients.1,2 Entyvio demonstrates early control of symptoms, sustained remission and mucosal healing3-7click here for more information

Licensed Indications

Ulcerative Colitis

Entyvio is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist.1,2

Clinical Data

Crohn’s Disease

Entyvio is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα).1,2

Clinical Data

Entyvio Mode of Action

Vedolizumab is a gut-selective immunosuppressive biologic drug. It is a humanised monoclonal antibody integrin antagonist. It binds specifically to the alpha-4, beta-7 (α4β7) integrin, which is preferentially expressed on gut-homing T-helper lymphocytes.1,2

Adverse events should be reported. In the United Kingdom, reporting forms and information can be found at www.mhra.gov.uk/yellowcard.

Adverse events should also be reported to Takeda by e-mail at

AE.GBR-IRL@takeda.com